MicronutrientsPhase 4NCT00379158
Comparison of the Efficacy and Acceptability of Three Types of Micronutrient Supplements in Ghana
A Phase 4 study testing Micronutrient supplements in people with Micronutrients, run by University of California, Davis.
Trial summary
1. At 12 mo of age, all three intervention groups will have significantly better iron and vitamin A status than the NI group. 2. Infants who receive the Foodlet or Nutributter will have significantly greater weight and length gains from 6 to 12 mo and higher indices of vitamin B6, riboflavin and zinc status at 12 mo… Read more about this study
- Who is it for?
- Ages 5 to 6 monthsHealthy volunteers can take part
- Conditions the study is for
- Micronutrients
- What is being tested?
- Micronutrient supplements
- How many people
- 393 participants
- Where
- No sites listed yet
- Study dates
- Oct 2003to Apr 2005
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 5 to 6 months
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- approximately 5 mo of age
- receiving breast milk
- free of congenital abnormality
- expected to stay in the town for at least the subsequent six months.
Who cannot join
- medically diagnosed chronic illness (including asthma or eczema)
About this study
Official title: Comparison of the Efficacy and Acceptability of Three Types of Micronutrient Supplements Added to Complementary Foods for Infants in Ghana
- At 12 mo of age, all three intervention groups will have significantly better iron and vitamin A status than the NI group.
- Infants who receive the Foodlet or Nutributter will have significantly greater weight and length gains from 6 to 12 mo and higher indices of vitamin B6, riboflavin and zinc status at 12 mo of age than the infants who receive the sprinkles containing iron and vitamin A only.
- Infants who receive Nutributter will have significantly greater weight and length gains from 6 to 12 mo and higher indices of vitamin A and essential fatty acid (linoleic, alpha-linolenic and docosahexaenoic, DHA) status at 12 mo of age than the infants who receive the Foodlet or sprinkles.
Read the detailed description
Study design
We propose to conduct a randomized controlled study of infants recruited from Maternal and Child Health centers in the town of Koforidua, located in eastern Ghana. There are 8 such centers located in various parts of the town, each of which serves the mothers and children in the immediate vicinity. The vast majority of infants born in Koforidua are brought to the MCH centers beginning a few weeks after birth for monthly weight monitoring. A list of all infants attending the MCH centers who are approximately 5 mo of age, have no congenital abnormality or chronic disease, and are currently breastfed will be created during each clinic day. From these lists we will randomly select approximately 34 infants per month (during a recruitment period of 9 mo) who will be invited to participate in the intervention trial. These infants will then be randomly assigned to one of three groups:
- "Sprinkles" group: Will receive micronutrient Sprinkles beginning at 6 mo of age.
- "Foodlet" group: Will receive crushable multiple micronutrient tablet beginning at 6 mo of age.
- "Nutributter" group: Will receive fat-based supplement (Nutributter) beginning at 6 mo of age
We have chosen not to include a negative control (placebo) group because there is a high rate of iron and vitamin A deficiency in this population, and we cannot leave children who are known to be anemic untreated during the 6-mo study period. Instead, we will assess a "Non-Intervention" (NI) group of infants at 12 mo of age, which will allow us to evaluate attained size and micronutrient status in the absence of any intervention. The NI group will be randomly selected from the subset of infants who were recorded on the MCH lists described above during the recruitment period for the intervention trial (and thus met the same selection criteria), but not randomly selected for the intervention trial. [We cannot take all of the infants who come to the MCH clinics each month because the field work would be unmanageable. Given the birth rate of 179/mo, there will be more than enough "left over" each month who won't be selected for the intervention, and from whom we can randomly select the non-intervention group once they reach 12 mo.] We plan to recruit approximately 9/mo for the NI group for a period of 9 months, starting 6 mo after we initiate recruitment for the intervention (i.e., when the "left-over" infants begin to reach 12 mo of age). The MCH lists will include contact information (address), so that we can find the NI mothers at 12 mo. When we contact them at 12 mo, we will confirm that their infants would have met the eligibility criteria for the intervention study (breastfed at 5 mo, and free of congenital abnormality, chronic disease or peanut allergy), and ask them to participate in the one-time assessment. At that time each NI family will be given compensation equivalent in value to the supplements provided to the intervention groups (such as a 6-mo supply of Nutributter).
Study site The study will be conducted in Koforidua, which has a population of about 87,000 and an average birth rate of 179/mo (between 1998 and 2001).
The University of Ghana will administer the project and provide scientific and technical support for the study. It will also provide office space for administrative tasks and laboratories for biochemical analyses of blood samples. UC Davis will provide supervision of the study through the Project Manager (Seth Adu-Afarwuah, a doctoral student at UC Davis), and will order and ship all of the necessary supplies and equipment.
Informed consent procedures: Approval for the study has been obtained from the UC Davis Human Subjects Review Committee and the University of Ghana (Noguchi Memorial Institute) Ethics Committee. Consent to conduct the study in the town will be obtained from the Koforidua Municipal Health Administration. Written consent to participate in the study will be obtained individually from the mothers of the infants. Consent forms explaining the purpose of the study, potential risks or discomfort, the rights of subjects and the benefits to the subjects will be available both in English and in the local language, Asante Twi. For illiterate mothers unable to read, the form will be read and explained to them in Asante Twi. To indicate their consent, mothers will be asked to either sign the consent form or thumb-print it.
- Conditions
- Micronutrients
- Being tested
- Micronutrient supplements
- Keywords
- multiple micronutrient supplements, home-fortification, complementary foods, infants, Ghana
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Micronutrient supplementsDrug
What is being measured
The primary outcome is the main question the study is designed to answer.
Growth (weight, length, head circumference)
Hemoglobin
Micronutrient status (Iron, retinol, B2, B6, zinc, plasma fatty acids)
Secondary outcomes (3)
Motor milestone acquisition
Morbidity
Energy intake from complementary foods
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Sep 2006 (estimated)
- Study startOct 2003
- Study completionApr 2005
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MicronutrientsStudies of the same condition, open and under way.
- More trials run by University of California, DavisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- None (open label)
- Enrolment
- 393 participants
Sponsor and investigators
- Lead sponsor
- University of California, Davis
- Sponsor type
- University, hospital or other
- Collaborators
- Nestlé Foundation, United States Agency for International Development (USAID)
- Responsible party
- Sponsor
- Investigators
- Kathryn G Dewey, PhD, Principal investigator, University of California, DavisAnna Lartey, PhD, Principal investigator, University of Ghana
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00379158
- Sponsor's protocol ID
- 200210085
- Status last verified
- May 2017
- First submitted
- 20 Sep 2006
- Last updated
- 30 May 2017
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 May 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of the Efficacy and Acceptability of Three Types of Micronutrient Supplements Added to Complementary Foods for Infants in Ghana
- ClinicalTrials.gov ID
- NCT00379158
- Acronym / sponsor ID
- 200210085
- Conditions
- Micronutrients
- Keywords
- multiple micronutrient supplements, home-fortification, complementary foods, infants, Ghana
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 393 participants
- Lead sponsor
- University of California, DavisUniversity, hospital or other
- Collaborators
- Nestlé Foundation, United States Agency for International Development (USAID)
- Study start
- Oct 2003
- Study completion
- Apr 2005
- First posted
- 21 Sep 2006 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- At 12 mo of age, all three intervention groups will have significantly better iron and vitamin A status than the NI group.
- Infants who receive the Foodlet or Nutributter will have significantly greater weight and length gains from 6 to 12 mo and higher indices of vitamin B6, riboflavin and zinc status at 12 mo of age than the infants who receive the sprinkles containing iron and vitamin A only.
- Infants who receive Nutributter will have significantly greater weight and length gains from 6 to 12 mo and higher indices of vitamin A and essential fatty acid (linoleic, alpha-linolenic and docosahexaenoic, DHA) status at 12 mo of age than the infants who receive the Foodlet or sprinkles.
Detailed description
Study design
We propose to conduct a randomized controlled study of infants recruited from Maternal and Child Health centers in the town of Koforidua, located in eastern Ghana. There are 8 such centers located in various parts of the town, each of which serves the mothers and children in the immediate vicinity. The vast majority of infants born in Koforidua are brought to the MCH centers beginning a few weeks after birth for monthly weight monitoring. A list of all infants attending the MCH centers who are approximately 5 mo of age, have no congenital abnormality or chronic disease, and are currently breastfed will be created during each clinic day. From these lists we will randomly select approximately 34 infants per month (during a recruitment period of 9 mo) who will be invited to participate in the intervention trial. These infants will then be randomly assigned to one of three groups:
- "Sprinkles" group: Will receive micronutrient Sprinkles beginning at 6 mo of age.
- "Foodlet" group: Will receive crushable multiple micronutrient tablet beginning at 6 mo of age.
- "Nutributter" group: Will receive fat-based supplement (Nutributter) beginning at 6 mo of age
We have chosen not to include a negative control (placebo) group because there is a high rate of iron and vitamin A deficiency in this population, and we cannot leave children who are known to be anemic untreated during the 6-mo study period. Instead, we will assess a "Non-Intervention" (NI) group of infants at 12 mo of age, which will allow us to evaluate attained size and micronutrient status in the absence of any intervention. The NI group will be randomly selected from the subset of infants who were recorded on the MCH lists described above during the recruitment period for the intervention trial (and thus met the same selection criteria), but not randomly selected for the intervention trial. [We cannot take all of the infants who come to the MCH clinics each month because the field work would be unmanageable. Given the birth rate of 179/mo, there will be more than enough "left over" each month who won't be selected for the intervention, and from whom we can randomly select the non-intervention group once they reach 12 mo.] We plan to recruit approximately 9/mo for the NI group for a period of 9 months, starting 6 mo after we initiate recruitment for the intervention (i.e., when the "left-over" infants begin to reach 12 mo of age). The MCH lists will include contact information (address), so that we can find the NI mothers at 12 mo. When we contact them at 12 mo, we will confirm that their infants would have met the eligibility criteria for the intervention study (breastfed at 5 mo, and free of congenital abnormality, chronic disease or peanut allergy), and ask them to participate in the one-time assessment. At that time each NI family will be given compensation equivalent in value to the supplements provided to the intervention groups (such as a 6-mo supply of Nutributter).
Study site The study will be conducted in Koforidua, which has a population of about 87,000 and an average birth rate of 179/mo (between 1998 and 2001).
The University of Ghana will administer the project and provide scientific and technical support for the study. It will also provide office space for administrative tasks and laboratories for biochemical analyses of blood samples. UC Davis will provide supervision of the study through the Project Manager (Seth Adu-Afarwuah, a doctoral student at UC Davis), and will order and ship all of the necessary supplies and equipment.
Informed consent procedures: Approval for the study has been obtained from the UC Davis Human Subjects Review Committee and the University of Ghana (Noguchi Memorial Institute) Ethics Committee. Consent to conduct the study in the town will be obtained from the Koforidua Municipal Health Administration. Written consent to participate in the study will be obtained individually from the mothers of the infants. Consent forms explaining the purpose of the study, potential risks or discomfort, the rights of subjects and the benefits to the subjects will be available both in English and in the local language, Asante Twi. For illiterate mothers unable to read, the form will be read and explained to them in Asante Twi. To indicate their consent, mothers will be asked to either sign the consent form or thumb-print it.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- None (open label)
Who may qualify
- Ages
- 5 to 6 months
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (4 listed)
- approximately 5 mo of age
- receiving breast milk
- free of congenital abnormality
- expected to stay in the town for at least the subsequent six months.
Key exclusion criteria (1 listed)
- medically diagnosed chronic illness (including asthma or eczema)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Micronutrient supplements | Drug | – |
Primary outcome
Growth (weight, length, head circumference)
Hemoglobin
Micronutrient status (Iron, retinol, B2, B6, zinc, plasma fatty acids)
3 secondary outcomes
Motor milestone acquisition
Morbidity
Energy intake from complementary foods
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 May 2017.
Related trials for Micronutrients
Recruiting
Micronutrient Supplementation and Chronotherapy in Children With ADHD
Attention Deficit Hyperactivity Disorder (ADHD)
Active, not recruiting
Iron Absorption From IFA and MMS Supplements in Kenyan Women During the Second Trimester of Pregnancy
Pregnancy
RecruitingObservational study
Mother and Offspring's Nutritional Status -Pregnancy After Maternal Bariatric Surgery
Bariatric Surgery, Pregnency
Not yet recruiting
Unflavored Powdered Multivitamin in Children
Selective Eating, Emotional Dysregulation
RecruitingPhase 3
Micronutrient Enhancement for Development and Health in Adolescents - The MEDHA Study
Neurodevelopment Outcome, Linear Growth
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kathryn G Dewey, PhD principal investigator
University of California, Davis
Anna Lartey, PhD principal investigator
University of Ghana
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Micronutrient supplements in people with Micronutrients, run by University of California, Davis.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 May 2017. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Growth (weight, length, head circumference). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 May 2017.